Establishment Labs Hldgs Inc - ESTA STOCK NEWS

Establishment Labs Holdings Inc. (NASDAQ: ESTA) has announced the launch of Motiva® Implants in China, the second largest market globally. The company expects rapid growth in China due to consumer appreciation for innovative technologies and a large segment willing to pay a premium for such products. The commercial launch coincided with the Motiva China International Academic Conference, and events also took place in Shanghai, Guangzhou, and Shenzhen. Establishment Labs received National Medical Products Administration (NMPA) approval in China for Motiva® Implants in November 2023.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced a securities purchase agreement with institutional accredited investors to purchase common shares or pre-funded warrants. Preliminary unaudited financial results for Q4 2023 show expected revenue in the range of $31.4 million to $31.8 million, in line with previous guidance. Full-year 2023 revenue is expected to be $165.0 million to $165.4 million, with a year-end cash position of approximately $39.1 million. The company will sell two million common shares or pre-funded warrants at $25.00 per share, expecting aggregate gross proceeds of approximately $50 million.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced that the Motiva Flora® SmoothSilk® Tissue Expander was used for the first time in the United States at the University of Texas MD Anderson Cancer Center in Houston by Mark Clemens, MD MBA FACS, Professor of Plastic Surgery. The recent FDA clearance and first procedure mark significant developments in the field of plastic and reconstructive surgery. The Flora® Tissue Expander includes several proprietary innovations, including Establishment Labs’ patented SmoothSilk® surface technology and an RFID-enabled, non-magnetic port, labeled as MR Conditional by the FDA. SmoothSilk® has been shown to produce the least amount of inflammation and foreign body response compared to other device surfaces. By being magnet-free, Flora avoids the interference that magnets cause during MRI and may improve the precision of radiation oncology treatment. Juan José Chacón-Quirós, Founder and CEO of Establishment Labs, emphasized the company's commitment to improving women’s health and wellness, stating that real innovation leads to better patient outcomes, and Flora is setting a new standard in breast reconstruction.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announces participation in the 42nd Annual J.P. Morgan Healthcare Conference

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announces participation in two investment conferences, including the 2023 Jefferies London Healthcare Conference and the Stephens Annual Investment Conference. CEO and Founder Juan José Chacón-Quirós and CFO Raj Denhoy will speak at the events, with live webcasts available on the company's investor relations website.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) has received NMPA approval in China for Motiva® Implants, marking their entry into the second largest global market for breast aesthetics. The company expects Chinese plastic surgeons to adopt their technology as their first choice, based on their success in South Korea.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) Announces Q3 2023 Financial Results: Revenue Up 0.8%, 2023 Revenue Guidance Increased to $165 Million, Loss from Operations Increases, FDA Clearance for Motiva Flora® SmoothSilk® Tissue Expander, Mia Femtech™ Clinical Study Data Released

Flora, the magnet-free and MR Conditional tissue expander, has been cleared for the U.S. market. Establishment Labs Holdings Inc. plans to announce its financial results for Q3 2023 on November 7, 2023, and will host a conference call to discuss those results.

Establishment Labs receives FDA clearance for Motiva Flora® SmoothSilk® Tissue Expander